Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions.
The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Martin Holst Lange
EVP of R&D, Chief Scientific Officer and Member of the Management Board
- Frederik Kier
Senior Vice President of Global Obesity Unit
- Mads Frederik Rasmussen
Senior VP & Head of Clinical Drug Development
- Emil Kongshøj Larsen
EVP of International Operations & Member of Management Board
- Thomas Rask Nielsen
SVP of Legal, Ethics & Comp, Bus Assu., IP & Security, Group Gen Coun and Member of Mgmt. Boar
- Elin Jager
SVP, Chief of Staff to CEO, Transformation & Sustainability and Member of Management Board
- Jamey Millar
Executive Vice President of US Operations & Member of Management Board
- John F. Kuckelman
SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board